Zoetis Inc. (NYSE:ZTS) Shares Purchased by Strategy Asset Managers LLC

Strategy Asset Managers LLC grew its stake in shares of Zoetis Inc. (NYSE:ZTS) by 3.5% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 1,822 shares of the company’s stock after purchasing an additional 62 shares during the quarter. Strategy Asset Managers LLC’s holdings in Zoetis were worth $356,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Axxcess Wealth Management LLC lifted its position in Zoetis by 17.4% during the 1st quarter. Axxcess Wealth Management LLC now owns 9,826 shares of the company’s stock worth $1,663,000 after acquiring an additional 1,458 shares during the period. Advisors Asset Management Inc. lifted its holdings in shares of Zoetis by 4.4% during the first quarter. Advisors Asset Management Inc. now owns 16,168 shares of the company’s stock worth $2,736,000 after purchasing an additional 678 shares during the period. Toronto Dominion Bank lifted its holdings in shares of Zoetis by 17.5% during the first quarter. Toronto Dominion Bank now owns 308,667 shares of the company’s stock worth $52,230,000 after purchasing an additional 46,001 shares during the period. Capital Research Global Investors increased its holdings in Zoetis by 2.3% in the 1st quarter. Capital Research Global Investors now owns 4,050,681 shares of the company’s stock worth $685,416,000 after buying an additional 90,330 shares during the period. Finally, Westwood Holdings Group Inc. lifted its stake in Zoetis by 4.1% during the 1st quarter. Westwood Holdings Group Inc. now owns 163,965 shares of the company’s stock valued at $27,745,000 after acquiring an additional 6,494 shares during the period. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Trading Up 0.1 %

Shares of NYSE:ZTS opened at $175.67 on Thursday. The business’s 50 day moving average price is $186.18 and its 200-day moving average price is $180.47. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The firm has a market capitalization of $79.26 billion, a price-to-earnings ratio of 33.02, a price-to-earnings-growth ratio of 2.69 and a beta of 0.90. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27.

Zoetis (NYSE:ZTS) last announced its earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same quarter last year, the business earned $1.36 earnings per share. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. On average, equities research analysts forecast that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be given a $0.432 dividend. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 annualized dividend and a dividend yield of 0.98%. Zoetis’s dividend payout ratio (DPR) is presently 32.52%.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on ZTS shares. Stifel Nicolaus increased their price objective on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. Argus upgraded Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. JPMorgan Chase & Co. upped their target price on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Piper Sandler lifted their price target on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Finally, BTIG Research upped their price objective on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $221.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.